Source comparison
Thymosin Alpha-1 vs. Other Immune-Modulating Peptides: Research Comparison
How does thymosin alpha-1 compare to other immune peptides investigated in oncology research? Thymosin Alpha-1 TLR-2 agonist, dendritic cell activation, T-cell maturation Phase III (completed) HCC, NSCLC, gastric cancer, melanoma Meta-analyses show 30–40% infe
This comparison does not assign a generated winner or score.
- How does thymosin alpha-1 compare to other immune peptides investigated in oncology research?
- Thymosin Alpha-1
- TLR-2 agonist, dendritic cell activation, T-cell maturation
- Phase III (completed)
- HCC, NSCLC, gastric cancer, melanoma
- Meta-analyses show 30–40% infection reduction; modest survival gains (2–3 months)
- Regulatory-approved adjunct in 30+ countries; strongest evidence for reducing treatment toxicity
- Thymalin
- Thymic peptide extract, broad immunostimulation
- Phase II (ongoing)
- Prostate cancer, breast cancer
- Limited peer-reviewed data; primarily observational studies
- Mechanism less characterised; fewer controlled trials than thymosin alpha-1
- LL-37 (Cathelicidin)
- Antimicrobial peptide, immune modulation
- Preclinical / Phase I
- Colon cancer, ovarian cancer
- Early-stage; mechanism shows promise but human efficacy unproven
- No Phase III data; theoretical benefit not yet validated
- Pentadecapeptide BPC-157
- Angiogenesis modulation, tissue repair
- Preclinical only
- None (animal models)
- No human oncology trials; safety in cancer context unknown
- Frequently marketed without oncology evidence; no clinical foundation for cancer use
- Thymosin alpha-1 stands apart because it has completed randomised, placebo-controlled, multi-centre Phase III trials. The gold standard for clinical evidence. Thymalin shares a similar immune-restoring premise but lacks the depth of published trial data. LL-37 and BPC-157 are biologically interesting but remain in early research stages; using them in cancer treatment is speculative at best. Real Peptides prioritises peptides with established research foundations. Thymalin represents our commitment to supplying compounds that researchers can investigate with confidence, backed by reproducible synthesis and third-party purity verification.